1. "Journal of Clinical Oncology"
  2. "Howard Scher"
Formats
  1. Meeting Abstract (251)
  2. Journal Article (71)
  3. Correspondence (1)
Groups
  1. Department of Medicine (323)
  2. Genitourinary Oncology Service (323)
  3. Solid Tumor Oncology Division (323)
  4. GSK Faculty (77)
  5. Hematologic Malignancies, Division of (71)
  6. Epidemiology and Biostatistics (62)

More Groups

People
  1. Howard Scher (323)
  2. Michael Morris (84)
  3. Dana Rathkopf (64)
  4. Susan Slovin (61)
  5. Daniel Danila (60)
  6. Martin Fleisher (40)

More People

Years
  1. 2023 (6)
  2. 2022 (3)
  3. 2021 (4)
  4. 2020 (9)
  5. 2019 (16)
  6. 2018 (16)

More Years

Publications
  1. Journal of Clinical Oncology (323)
Publishers
  1. American Society of Clinical Oncology (323)

Results (323)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase 2, randomized, open-label study comparing the effects of darolutamide versus enzalutamide monotherapy on serum testosterone levels in patients with hormone-naive prostate cancer: ARAMON study
    Meeting Abstract

    Gao, X.; Smith, M. R.; Scher, H. I.; Verholen, F.; Adorjan, P.; Dissanayake, M.; Laccetti, A. L.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A phase Ib/II study of intermittent talazoparib plus temozolomide in patients with metastatic castration-resistant prostate cancer (mCRPC) and no mutations in DNA damage repair (DDR)
    Meeting Abstract

    Autio, K. A.; Kyriakopoulos, C.; Xiao, H.; Emamekhoo, H.; Danila, D. C.; Devitt, M. E.; Riedel, E.; Jan, M.; Scher, H. I.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Analysis of androgen receptor dynamics through immunofluorescent staining of circulating tumor cells in castration-resistant prostate cancer
    Meeting Abstract

    Barnett, E.; Gupta, S.; Erazo, T.; Lam, E.; Carbone, E.; Zanone, M.; Nystrom, L.; Gajar, R. N.; Wenstrup, R.; Scher, H. I.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Prognostic and predictive implications of plasma ctDNA in guiding first-line targeted therapy for metastatic HER2 -mutant non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Liu, S. Y.; Jee, J.; Santini, F. C.; Schoenfeld, A. J.; Eichholz, J.; Johnson, K.; Martinez, A.; Guo, J.; Riaz, N.; Lee, N. Y.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A phase 2 study of immunogenic cell death inducer PT-112 in patients with metastatic castration-resistant prostate cancer
    Meeting Abstract

    Bryce, A. H.; Karp, D. D.; Tagawa, S. T.; Nordquist, L. T.; Rathkopf, D. E.; Adra, N.; Dorff, T. B.; Baeck, J.; O'Donnell, J. F.; Ames, T. D.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Automated analysis of FDG-PET/CT imaging to monitor heterogeneous disease response in metastatic castration-resistant prostate cancer
    Meeting Abstract

    Barnett, E.; Woo, S.; Perk, T. G.; Munian-Govindan, R.; Lokre, O.; Gajar, R. N.; Erazo, T.; Carbone, E.; Morris, M. J.; Vargas, H. A.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Chromosomal instability (CIN) in circulating tumor cells (CTC) predicts for taxane sensitivity in metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Keegan, N. M.; Arfe, A.; Barnett, E.; Cohn, E. D.; Zhao, J.; Carbone, E.; Zanone, M.; Anderson, A.; Wenstrup, R.; Scher, H. I.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Genomic alterations and evolution in patients with prostate cancer with histologic evidence of neuroendocrine differentiation
    Meeting Abstract

    Barnett, E.; Carbone, E.; Keegan, N. M.; Vasselman, S. E.; Nweji, B.; Zaidi, S.; Scher, H. I.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Clinical annotations for prostate cancer research: Defining data elements, creating a reproducible analytical pipeline, and assessing data quality
    Meeting Abstract

    Keegan, N. M.; Vasselman, S. E.; Barnett, E.; Nweji, B.; Carbone, E.; Blum, A.; Morris, M. J.; Rathkopf, D. E.; Slovin, S. F.; Danila, D. C.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Schlafen 11 (SLFN11), a putative predictive biomarker of platinum/PARPi response, is frequently detected on circulating tumor cells (CTCs) in advanced prostate cancer
    Meeting Abstract

    Scher, H. I.; Fernandez, L.; Cunningham, K.; Elphick, N.; Barnett, E.; Lee, J.; Gilbertson, C.; Carbone, E.; Bourdon, D.; Blankfard, M.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save